Scott Buzby

Transcatheter mitral valve repair in addition to medical therapy led to a lower rate of CV events and hospitalizations and better health status compared with medical therapy alone for patients with HF and moderate to severe mitral regurgitation.Results of the randomized RESHAPE-HF2 trial, which assessed outcomes after transcatheter mitral valve repair with MitraClip (Abbott Vascular) for the

Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.The full results of the phase 3 OCEANIC-AF trial of asundexian (Bayer) for the prevention of stroke and systemic embolism in patients with AF were presented at the European Society of

A bedside cardiac troponin test could reduce the time patients with ACS spend in the ED by nearly 45 minutes, with the availability of a doctor to assess the situation and move them to the cardiac ward, a speaker reported.The results of the WESTCOR-POC trial were presented at the European Society of Cardiology Congress.

Edoxaban monotherapy for patients with atrial fibrillation and stable coronary disease reduced risk for adverse clinical events, mainly driven by lower bleeding risk, compared with dual antiplatelet therapy, a speaker reported.

High consumption of ultraprocessed food, especially processed meats and sugar-sweetened beverages, was associated with elevated risk for heart disease and stroke, researchers reported.

SGLT2 inhibition may prevent cancer therapy-related cardiac dysfunction and improve other outcomes in patients with diabetes undergoing cancer therapy, researchers reported.An analysis of the effects various SGLT2 inhibitors on CV outcomes in patients with cancer undergoing treatment who had diabetes but no history of cardiomyopathy or HF was presented at the Global Cardio Oncology Summit and

Women with obesity and atherosclerotic CVD without diabetes experience fewer CV events vs. men enrolled in the SELECT trial; however, semaglutide

Improvements in exercise capacity and quality of life associated with aficamten coincided with significant cardiac remodeling and replacement fibrosis in patients with obstructive hypertrophic cardiomyopathy, a speaker reported.Results of a SEQUOIA-HCM substudy were presented at the European Society of Cardiology Congress and simultaneously published in the Journal of the American College of

Treatment of obesity-related HF with preserved ejection fraction with semaglutide 2.4 mg improved body weight, physical function and HF symptoms regardless of the extent of patient frailty, a speaker reported.

Semaglutide 2.4 mg was linked to early, sustained improvement in exercise function among patients with obesity-related HF and improved most among those with the largest proportionate weight loss, a speaker reported.